Trial Profile
A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumours and HER2 Positive Circulating Tumour Cells
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Vinorelbine
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 10 Nov 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 02 Oct 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
- 22 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.